Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation.

Jacob W Greenberg Hogyoung KimMiae AhnAhmed A MoustafaHe ZhouPedro C BarataA Hamid BoularesAsim B Abdel-MageedLouis S Krane

Published in: Cancers (2022)

Tipifarnib attenuates both the exosome endosomal sorting complex required for endosomal sorting complex required for transport (ESCRT)-dependent and ESCRT-independent pathways, thereby blocking exosome biogenesis and secretion as well as downregulating PD-L1 on SS and SR cells.

Keyphrases

renal cell carcinoma
induced apoptosis
cell cycle arrest
signaling pathway
cell death